Request Demo
Last update 26 Oct 2025
GB-263
Last update 26 Oct 2025
Overview
Basic Info
Drug Type Trispecific antibody |
Synonyms GB 263, GB 263T, GB-263 + [2] |
Target |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with GB-263NCT05332574
A Phase I/II, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific EGFR/cMET/cMET Antibody GB263T in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
100 Clinical Results associated with GB-263
Login to view more data
100 Translational Medicine associated with GB-263
Login to view more data
100 Patents (Medical) associated with GB-263
Login to view more data
100 Deals associated with GB-263
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 27 Sep 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Australia | 17 May 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05332574 (ESMO2024) Manual  | Phase 1/2 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 15 | GB263T 140-1680 mg IV weekly | zjcjtwxlqp(crcvgetkol) = wjmlubbbyg nunjckwtqv (hbbthqrcwl ) View more | Positive | 14 Sep 2024 |
GB263T 140-1680 mg IV weekly (EGFR sensitive mutations and progressed after third-generation EGFR-TKI treatment) | zjcjtwxlqp(crcvgetkol) = klehtcyaim nunjckwtqv (hbbthqrcwl ) | ||||||
Phase 1/2 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 6 | vzuqgkmfno(wpzkisvcff) = todsnlyvlr knjfmuczfr (cphharhtut ) View more | Positive | 26 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free